STOCK TITAN

Co-Diagnostics: reverse splits up to 1-for-750 approved

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Co-Diagnostics, Inc. (CODX) shareholders approved an amendment to the 2025 Equity Incentive Plan on November 13, 2026, making it effective that day. It adds 2,000,000 shares to the plan’s authorized issuance; the maximum for awards is 2,223,333 shares, plus shares that become available from canceled or forfeited 2015 plan awards. Incentive stock options have the same 2,223,333-share maximum. Other plan terms were not materially changed.

Shareholders authorized one or more reverse splits at ratios no less than 1-for-2, with cumulative effect capped at 1-for-750; the board may set ratios and timing within 12 months. They approved potential exercise of warrants for 3,404,724 shares at $1.56 each and issuance of shares upon conversion of secured convertible notes. They also approved a one-third quorum threshold, adopted a non-binding executive-compensation resolution, ratified Tanner LLC as independent registered public accounting firm for the year ending December 31, 2026, and elected Dwight Egan, Eugene Durenard, Richard Serbin, James Nelson and Edward Murphy as directors for one-year terms.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Increase in plan share authorization 2,000,000 shares Approved November 13, 2026; effective upon approval
Maximum shares for plan awards 2,223,333 shares Under the amended 2025 Equity Incentive Plan, plus shares becoming available from canceled or forfeited 2015 plan awards
Incentive stock-option limit 2,223,333 shares Maximum shares issuable upon exercise of incentive stock options under the amended plan
Shares covered by warrant exercise approval 3,404,724 shares Potential exercise approved by shareholders; warrants issued August 3, 2026
Warrant exercise price $1.56 per share Warrants covered by the shareholder approval
Reverse-split authorization range Not less than 1-for-2; cumulative effect not to exceed 1-for-750 Shareholder approval gives the board authority to determine ratios and timing within 12 months after the meeting
Quorum threshold One-third of votes entitled to be cast Shareholders approved an amendment to the Articles of Incorporation
incentive stock options financial
"maximum number of shares of Common Stock that may be issued on the exercise of incentive stock options"
Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.
broker non-votes regulatory
"Votes For | Votes Withheld | Broker Non-votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
secured convertible notes financial
"shares of common stock issuable upon conversion of the secured convertible notes"
A secured convertible note is a loan a company takes that is backed by specific assets (like equipment or accounts) and can later be turned into company shares instead of being repaid in cash. Think of it as a mortgage-style IOU that includes an option to swap the debt for ownership; the security gives lenders priority if the company fails, while the conversion feature can dilute existing shareholders but may help the company raise funds more cheaply than straight equity.
quorum technical
"one-third of the votes entitled to be cast on a matter shall constitute a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
inducement agreement financial
"pursuant to that certain inducement agreement dated July 30, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did CODX shareholders authorize for the 2025 Equity Incentive Plan?

The amendment added 2,000,000 shares to the plan’s authorized issuance, and the maximum for awards is 2,223,333 shares, with additional shares becoming available when certain 2015 plan awards are canceled or forfeited. The amendment took effect on November 13, 2026.

What reverse stock split did CODX shareholders approve?

Shareholders authorized one or more reverse splits at ratios no less than 1-for-2, with the cumulative effect not to exceed 1-for-750. The board may determine the final ratio or ratios and timing within 12 months after the meeting, without further shareholder approval or authorization.

What CODX warrant and convertible-note share issuances did shareholders approve?

Shareholders approved the potential exercise of warrants to purchase an aggregate of 3,404,724 shares at $1.56 per share. The warrants were issued on August 3, 2026, under an inducement agreement dated July 30, 2026. Shareholders also approved shares issuable upon conversion of secured convertible notes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001692415 0001692415 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 13, 2026

 

CO-DIAGNOSTICS, INC.

 

(Exact name of registrant as specified in its charter)

 

Utah   1-38148   46-2609363
(State or other jurisdiction of   (Commission   (IRS Employer
incorporation or organization)   File Number)   Identification Number)

 

2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109

(Address of principal executive offices)

 

(801) 438-1036

(Issuer’s telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   CODX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 13, 2026, Co-Diagnostics, Inc. (the “Company”) held a court-ordered special meeting of shareholders (the “Special Meeting”). At the Special Meeting, the Company’s shareholders approved Amendment No. 1 (the “Plan Amendment”) to the Co-Diagnostics, Inc. 2025 Equity Incentive Plan (the “Plan”). The Company’s Board of Directors had previously approved the Plan Amendment, subject to shareholder approval. The Plan Amendment became effective when the shareholders approved it on November 13, 2026.

 

The Plan Amendment increases the number of shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), authorized for issuance under the Plan by 2,000,000 shares. As amended, the Plan provides that, subject to adjustment as provided in the Plan, the maximum number of shares of Common Stock that may be issued or transferred under awards granted under the Plan is 2,223,333 shares. To that number are added any shares that become available for issuance under the Plan when awards granted under the Company’s Amended and Restated 2015 Long-Term Incentive Plan (the “2015 Plan”) are cancelled or forfeited. The Plan Amendment also sets the maximum number of shares of Common Stock that may be issued on the exercise of incentive stock options granted under the Plan at 2,223,333 shares, subject to adjustment as provided in the Plan. Apart from the increase in the share reserve, the Plan Amendment does not materially change the terms of the Plan. The Company’s employees, non-employee directors and consultants, including its executive officers, are eligible to receive awards under the Plan.

 

The material terms of the Plan, as amended by the Plan Amendment, are summarized in the Company’s definitive proxy statement on Schedule 14A for the Special Meeting. That proxy statement was filed with the Securities and Exchange Commission on October 26, 2026 (the “Proxy Statement”). The summary appears under the caption “Proposal No. 2 — Approval of an Increase in the Number of Shares Authorized for Issuance Under the Co-Diagnostics, Inc. 2025 Equity Incentive Plan” and is incorporated herein by reference. The description above and the summary in the Proxy Statement are not complete. They are qualified in their entirety by the full text of the Plan Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

 

The voting results for the Plan Amendment are reported under Item 5.07 of this Current Report on Form 8-K.

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On November 13, 2026, the Company held a Special Meeting of shareholders at which the following matters were voted on:

 

Proposal No. 1: Election of Directors. The Company’s shareholders elected for a one-year term each of the persons nominated for election as a director. The following table sets forth the vote of the shareholders at the meeting with respect to the election of directors:

 

Nominee   Votes For   Votes Withheld   Broker Non-votes
Dwight Egan   1,280,609   314,073   2,092,364
Eugene Durenard   1,461,469   133,213   2,092,364
Richard Serbin   1,461,461   133,221   2,092,364
James Nelson   1,459,292   135,390   2,092,364
Edward Murphy   1,447,019   147,663   2,092,364

 

There were no abstentions with respect to the election of directors.

 

 

 

 

Proposal No. 2: A proposal to approve an increase in the number of shares of common stock authorized for issuance under the Company’s Co-Diagnostics, Inc. 2025 Equity Incentive Plan, as described in the Proxy Statement. This proposal was adopted.

 

For  Against  Abstain  Broker Non-votes
1,017,401  571,209  6,072  2,092,364

 

Proposal No. 3: A proposal to adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement under “Executive Compensation.” This proposal was adopted.

 

For  Against  Abstain  Broker Non-votes
1,099,440  486,505  8,737  2,092,364

 

Proposal No. 4: A proposal to ratify the Audit Committee’s appointment of Tanner LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2026. This proposal was ratified.

 

For  Against  Abstain  Broker Non-votes
2,908,169  752,419  26,458  -

 

Proposal No. 5: A proposal to approve an amendment to the Company’s Articles of Incorporation to provide that shares representing one-third of the votes entitled to be cast on a matter shall constitute a quorum for the transaction of business at a meeting of shareholders. This proposal was approved.  

 

For   Against   Abstain   Broker Non-votes
1,163,672   427,187   3,823   2,092,364

 

Proposal No. 6: A proposal to approve the potential exercise of the new warrants to purchase an aggregate of 3,404,724 shares of common stock at an exercise price of $1.56 per share that were issued on August 3, 2026 pursuant to that certain inducement agreement dated July 30, 2026, for which stockholder approval is required in accordance with Nasdaq Listing Rule 5635(d). This proposal was approved.

 

For  Against  Abstain  Broker Non-votes
1,304,745  284,259  5,516  2,092,364

 

Proposal No. 7: A proposal to approve, for purposes of Nasdaq Listing Rule 5635(d), the issuance of shares of common stock issuable upon conversion of the secured convertible notes issued in connection with the financing transaction described in the Proxy Statement. This proposal was approved.

 

For   Against  Abstain  Broker Non-votes
546,401   442,538  605,743  2,092,364

 

Proposal No. 8: A proposal to approve an amendment to the Company’s Articles of Incorporation, as amended, to effect one or more reverse stock splits of the Company’s issued and outstanding shares of common stock, on one or more occasions, at a ratio of not less than 1-for-2, with the cumulative effect of all such reverse stock splits not to exceed 1-for-750, such final ratio or ratios and the timing and number of any reverse stock splits to be determined by our Board at any time within twelve months following the Special Meeting, without further approval or authorization of our stockholders, as described in the Proxy Statement. This proposal was approved.

 

For  Against  Abstain  Broker Non-votes
2,742,151  940,861  4,034   -

 

Proposal No. 9: A proposal to approve any adjournments or postponements of the Special Meeting. This proposal was approved.

 

For  Against  Abstain  Broker Non-votes
3,114,883  549,187  22,976  -

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
10.1#   Amendment No. 1 to the Co-Diagnostics, Inc. 2025 Equity Incentive Plan
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

# Indicates a management contract or compensatory plan or arrangement.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  CO-DIAGNOSTICS, INC.
     
Date: November 13, 2026 By: /s/ Dwight H. Egan
  Name: Dwight Egan
  Title:

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading